Stock Details
BIIB is Biogen Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 206.45$. Average daily volumn in 3 months 1.12M. Market cap 29.24B



Stock symbol : BIIB. Exchange : NasdaqGS. Currency : USD
Lastest price : 199.65$. Total volume : 972.55k. Market state POSTPOST
Click reload if you want to check the lastest price on market!!!

Biogen Inc. (BIIB)
Last Price
199.65$
Change
6.56
Volume
972.55k

Previous Close193.09
Open195.33
Day Range194.49-199.78
Bid198.88 x 900
Ask199.65 x 2.2k
Volume972.55k
Average Volume1.12M
Market Cap29.24B
Beta0.42
52 Week Range187.16-468.55
Trailing P/E20.43
Foward P/E12.42
Dividend (Yield %)N/A
Ex-Dividend DateN/A



Financial Details


According to Biogen Inc.'s financial reports the company's revenue in 2021 were 10.98B an decrease(-23.08%) over the years 2020 revenue that were of 13.44B. In 2021 the company's total earnings were 1.56B while total earnings in 2020 were 4B(-75%).


Loading ...



Organization

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXAB... I, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Market Cap:
29.24B
Revenue:
10.98B
Total Assets:
23.88B
Total Cash:
2.26B


News about "Biogen Inc."

biogen-inc-expected-to-post-q2-2022-earnings-of-327-per-share-nasdaqbiib-image

Biogen Inc. Expected to Post Q2 2022 Earnings of $3.27 Per Share (NASDAQ:BIIB)

Source from : Defense World - 14 days ago

Biogen Inc. (NASDAQ:BIIB โ€“ Get Rating) โ€“ Equities research analysts at William Blair dropped their Q2 2022 earnings per share (EPS) estimates for shares of Biogen in a research report issued on ...See details»


oppenheimer-comments-on-biogen-incs-fy2022-earnings-nasdaqbiib-image

Oppenheimer Comments on Biogen Inc.โ€™s FY2022 Earnings (NASDAQ:BIIB)

Source from : Defense World - 12 days ago

Analysts at Oppenheimer decreased their FY2022 earnings per share estimates for shares of Biogen in a research report issued on Wednesday, May 4th. Oppenheimer analyst J. Olson now expects that the ...See details»


biogen-plans-1b-in-cost-savings-as-ceo-steps-down-image

Biogen plans $1B in cost-savings as CEO steps down

Source from : The Business Journals - 17 days ago

After more than five years at the helm of embattled Biogen Inc., Michel Vounatsos is stepping down as the company plans "additional cost-reduction and productivity measures" to save about $1 billion.See details»


biogen-ceo-to-step-down-drugmaker-pulls-back-on-alzheimers-drug-aduhelm-image

Biogen CEO to step down; drugmaker pulls back on Alzheimer's drug Aduhelm

Source from : Reuters - 17 days ago

Biogen Inc said on Tuesday that chief executive Michel Vounatsos will step down and that the company is pulling back on selling its controversial Alzheimer's drug Aduhelm, in what appears to be a ...See details»


investment-analysts-weekly-ratings-updates-for-biogen-biib-image

Investment Analystsโ€™ Weekly Ratings Updates for Biogen (BIIB)

Source from : ETF Daily News - 11 days ago

Biogen stock opened at $193.61 on Monday. Biogen Inc. has a one year low of $190.65 and a one year high of $468.55. The companyโ€™s fifty day moving average price is $208.69 and its two-hundred day ...See details»


how-many-biogen-inc-nasdaqbiib-shares-do-institutions-own-image

How Many Biogen Inc. (NASDAQ:BIIB) Shares Do Institutions Own?

Source from : Yahoo News - 4 days ago

If you want to know who really controls Biogen Inc. ( NASDAQ:BIIB ), then you'll have to look at the makeup of ...See details»


the-petri-dish-biogen-seeks-accelerated-approval-for-second-alzheimers-drug-image

The Petri Dish: Biogen seeks accelerated approval for second Alzheimer's drug

Source from : The Business Journals - 9 days ago

Biogen Inc. and development partner Eisai are looking to get their next Alzheimer's drug to market using the FDA's accelerated approval pathway โ€” the same route they used for controversy-laden Aduhelm ...See details»


biogen-faces-tough-rebuild-after-casting-off-its-troubled-alzheimers-drug-image

Biogen Faces Tough Rebuild After Casting Off Its Troubled Alzheimerโ€™s Drug

Source from : Wall Street Journal - 16 days ago

Biogen Inc. must now reckon with declining sales of drugs facing heavy competition and the risky odds of finding success in its pipeline, after giving up on the Alzheimerโ€™s therapy that was supposed ...See details»


When the Price of Biogen Inc. Common Stock BIIB Talks, People Listen

Source from : news.stocktradersdaily - 6 days ago

Buy BIIB over 167.96 target 200.41 stop loss @ 167.47 Details; The technical summary data tells us to buy BIIB near 167.96 with an upside targe ...See details»


Biogen Walks Away From Alzheimerโ€™s Flop With CEO Set to Depart

Source from : Bloomberg - 17 days ago

Biogen Inc.โ€™s chief executive officer will depart and the biotechnology company is planning more deep cost cuts as it tries to move beyond a disastrous rollout for its Alzheimerโ€™s disease drug ...See details»


Biogen Inc. (BIIB) Q1 Earnings Miss Estimates

Source from : Yahoo Finance - 17 days ago

Biogen Inc. (BIIB) came out with quarterly earnings of $3.62 per share, missing the Zacks Consensus Estimate of $4.41 per share. This compares to earnings of $5.34 per share a year ago.See details»


change-at-top-for-massachusetts-based-biogen-after-alzheimers-drug-flops-image

Change at top for Massachusetts-based Biogen after Alzheimer's drug flops

Source from : WCVB Channel 5 Boston - 17 days ago

Biogen will replace its CEO and largely abandon marketing of its controversial Alzheimer's drug less than a year after the medication's launch triggered backlash.See details»


eisai-biogen-seek-accelerated-approval-for-their-second-alzheimers-drug-image

Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug

Source from : YAHOO!Finance - 10 days ago

Eisai Co Ltd (OTC: ESALY) has completed the rolling submission of the FDA marketing application under the accelerated approval for lecanemab (BAN2401) for mild cognitive impairment (MCI) due to ...See details»


Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know

Source from : Yahoo - 18 days ago

Biogen Inc. (BIIB) closed the most recent trading day at $210.41, moving +1.68% from the previous trading session. The stock lagged the S&P 500's daily gain of 2.48%. Elsewhere, the Dow gained 1 ...See details»